Monoclonal Antibodies Market Size, Share & Trends Report

Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Source (Chimeric, Murine, Humanized, Human), By Type of Production, By Indication (Cancer, Autoimmune, Inflammatory, Infectious, Microbial, Viral Diseases), By End-use And Segment Forecasts, 2018 - 2024

  • Published Date: Nov, 2016
  • Base Year for Estimate: 2015
  • Report ID: GVR-1-68038-280-8
  • Format: Electronic (PDF)
  • Historical Data: 2013 - 2015
  • Number of Pages: 115

Market segmentation

  • Global Monoclonal Antibodies Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
    • Murine
    • Chimeric
    • Humanized
    • Human 
  • Global Monoclonal Antibodies Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
    • In Vivo
    • In Vitro
  • Global Monoclonal Antibodies Indication Outlook (Revenue, USD Billion, 2013 - 2024)
    • Cancer
    • Autoimmune Diseases
    • Inflammatory Diseases
    • Infectious Diseases
    • Microbial Diseases
    • Others
  • Global Monoclonal Antibodies End-use Outlook (Revenue, USD Billion, 2013 - 2024)
    • Hospitals
    • Research Institutes
    • Others
  • Monoclonal Antibodies Regional Outlook (Revenue, USD Billion, 2013 - 2024)
    • North America
      • The U.S.
        • The U.S. Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • Murine
          • Chimeric
          • Humanized
          • Human
        • The U.S. Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • In Vivo
          • In Vivo
        • The U.S. Indication Outlook (Revenue, USD Billion, 2013 - 2024)
          • Cancer
          • Autoimmune Diseases
          • Inflammatory Diseases
          • Infectious Diseases
          • Microbial Diseases
          • Others
        • The U.S. End-Use Outlook (Revenue, USD Billion, 2013 - 2024)
          • Hospitals
          • Research Institutes
          • Others
      • Canada
        • Canada Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • Murine
          • Chimeric
          • Humanized
          • Human
        • Canada Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • In Vivo
          • In Vivo
        • Canada Indication Outlook (Revenue, USD Billion, 2013 - 2024)
          • Cancer
          • Autoimmune Diseases
          • Inflammatory Diseases
          • Infectious Diseases
          • Microbial Diseases
          • Others
        • Canada End-Use Outlook (Revenue, USD Billion, 2013 - 2024)
          • Hospitals
          • Research Institutes
          • Others
    • Europe
      • The U.K.
        • The U.K. Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • Murine
          • Chimeric
          • Humanized
          • Human
        • The U.K. Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • In Vivo
          • In Vivo
        • The U.K. Indication Outlook (Revenue, USD Billion, 2013 - 2024)
          • Cancer
          • Autoimmune Diseases
          • Inflammatory Diseases
          • Infectious Diseases
          • Microbial Diseases
          • Others
        • The U.K. End-Use Outlook (Revenue, USD Billion, 2013 - 2024)
          • Hospitals
          • Research Institutes
          • Others
      • Germany
        • Germany Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • Murine
          • Chimeric
          • Humanized
          • Human
        • Germany Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • In Vivo
          • In Vivo
        • Germany Indication Outlook (Revenue, USD Billion, 2013 - 2024)
          • Cancer
          • Autoimmune Diseases
          • Inflammatory Diseases
          • Infectious Diseases
          • Microbial Diseases
          • Others
        • Germany End-Use Outlook (Revenue, USD Billion, 2013 - 2024)
          • Hospitals
          • Research Institutes
          • Others
    • Asia Pacific
      • Japan
        • Japan Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • Murine
          • Chimeric
          • Humanized
          • Human
        • Japan Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • In Vivo
          • In Vivo
        • Japan Indication Outlook (Revenue, USD Billion, 2013 - 2024)
          • Cancer
          • Autoimmune Diseases
          • Inflammatory Diseases
          • Infectious Diseases
          • Microbial Diseases
          • Others
        • Japan End-Use Outlook (Revenue, USD Billion, 2013 - 2024)
          • Hospitals
          • Research Institutes
          • Others
      • China
        • China Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • Murine
          • Chimeric
          • Humanized
          • Human
        • China Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • In Vivo
          • In Vivo
        • China Indication Outlook (Revenue, USD Billion, 2013 - 2024)
          • Cancer
          • Autoimmune Diseases
          • Inflammatory Diseases
          • Infectious Diseases
          • Microbial Diseases
          • Others
        • China End-Use Outlook (Revenue, USD Billion, 2013 - 2024)
          • Hospitals
          • Research Institutes
          • Others
      • India
        • India Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • Murine
          • Chimeric
          • Humanized
          • Human
        • India Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • In Vivo
          • In Vivo
        • India Indication Outlook (Revenue, USD Billion, 2013 - 2024)
          • Cancer
          • Autoimmune Diseases
          • Inflammatory Diseases
          • Infectious Diseases
          • Microbial Diseases
          • Others
        • India End- Use Outlook (Revenue, USD Billion, 2013 - 2024)
          • Hospitals
          • Research Institutes
          • Others
    • Latin America
      • Mexico
        • Mexico Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • Murine
          • Chimeric
          • Humanized
          • Human
        • Mexico Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • In Vivo
          • In Vivo
        • Mexico Indication Outlook (Revenue, USD Billion, 2013 - 2024)
          • Cancer
          • Autoimmune Diseases
          • Inflammatory Diseases
          • Infectious Diseases
          • Microbial Diseases
          • Others
        • Mexico End-Use Outlook (Revenue, USD Billion, 2013 - 2024)
          • Hospitals
          • Research Institutes
          • Others
      • Brazil
        • Brazil Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • Murine
          • Chimeric
          • Humanized
          • Human
        • Brazil Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • In Vivo
          • In Vivo
        • Brazil Indication Outlook (Revenue, USD Billion, 2013 - 2024)
          • Cancer
          • Autoimmune Diseases
          • Inflammatory Diseases
          • Infectious Diseases
          • Microbial Diseases
          • Others
        • Brazil End-Use Outlook (Revenue, USD Billion, 2013 - 2024)
          • Hospitals
          • Research Institutes
          • Others
    • MEA
      • South Africa
        • South Africa Source Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • Murine
          • Chimeric
          • Humanized
          • Human
        • South Africa Production Type Outlook (Revenue, USD Billion, 2013 - 2024)
          • In Vivo
          • In Vivo
        • South Africa Indication Outlook (Revenue, USD Billion, 2013 - 2024)
          • Cancer
          • Autoimmune Diseases
          • Inflammatory Diseases
          • Infectious Diseases
          • Microbial Diseases
          • Others
        • South Africa End-Use Outlook (Revenue, USD Billion, 2013 - 2024)
          • Hospitals
          • Research Institutes
          • Others

Report content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2013 to 2024
  • Market estimates and forecast for product segments up to 2024
  • Regional market size and forecast for product segments up to 2024
  • Market estimates and forecast for application segments up to 2024
  • Regional market size and forecast for application segments up to 2024
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.